Mouse Anti-MFGE8 Recombinant Antibody (clone Mc3) (CAT#: FAMAB-0225CQ)

Figure 1 In vitro adhesion, migration and survival assays to measure effect of MFGE8 on SKOV-3 cells.

Inhibition of adhesion to 5 µg/mL MFGE8 by 10 µg/mL anti-huMFGE8 (hMc3) or a negative control (Rituximab, Ritux).(h) Inhibition of migration to 5 µg/mL huMFGE8 by 10µg/mL anti-huMFGE8 hMc3, as compared to negative control (Ritux). (j) Inhibition of survival in the presence of 10 µg/mL huMFGE8, by 10µg/mL hMc3 or the negative antibody. 100% = basal level of A.U. in the presence of MFGE8. Data are represented as Box-and-whiskers graphs showing the minimum (lower error bar), 25th percentile-median-75th percentile and maximum (upper error bar) values. N=4 (except 3j: N=5). *** = P<0.001; ** = P<0.01; * = P<0.05 compared to Ctrl = PBS in 3b, g; to 0.312 µg/ml MFGE8 in 3i; or to Ctrl = MFGE8 in 3c, d, e, h, j..

Tibaldi, L., Leyman, S., Nicolas, A., Notebaert, S., Dewulf, M., Ngo, T. H., ... & Théry, C. (2013). New blocking antibodies impede adhesion, migration and survival of ovarian cancer cells, highlighting MFGE8 as a potential therapeutic target of human ovarian carcinoma. PLoS One, 8(8), e72708.

Figure 2 Identification of new antibodies blocking either adhesion, migration or survival induced by MFGE8.

(a) Effect of 10 new anti-MFGE8 antibodies (10 or 50 µg/mL) on adhesion to MFGE8 (adhesion assay), as compared to hMC3. 100% adhesion corresponds to 5 µg/mL MFGE8 coating without antibodies (ctrl). Example of the screening experiments, performed once with each of the 40 new antibodies. Black arrows indicate the antibodies selected for further characterization. (b) Dose–response effect of the 5 selected antibodies, as compared to hMC3 in the adhesion assay. (c) Dose–response effect of the 5 selected antibodies, as compared to hMC3 in the migration assay. 100% migration corresponds to 5 µg/mL MFGE8 without antibodies. (d) Dose–response effect of the 5 selected antibodies, as compared to hMC3 in the survival assay. 100% survival corresponds to 10 µg/mL recombinant MFGE8 without antibodies. Box-and-whiskers graphs as in Figure 3. N=4 (except in (c) for 215A9 -10 µg/mL and 311A7 -0.625 µg/mL: N=3 and for hMc3: N=2; in (b) for 215A9 -5µg/mL: N=2). *** = P<0.001; ** = P<0.01; * = P<0.05 compared to the lowest antibody concentration (0.5 or 0.625 µg/ml) for each individual antibody in 4b, c, d.

Tibaldi, L., Leyman, S., Nicolas, A., Notebaert, S., Dewulf, M., Ngo, T. H., ... & Théry, C. (2013). New blocking antibodies impede adhesion, migration and survival of ovarian cancer cells, highlighting MFGE8 as a potential therapeutic target of human ovarian carcinoma. PLoS One, 8(8), e72708.